The fact that nearly 30% of early-diagnosed breast cancer cases might eventually develop recurrent or metastatic disease ([@bib36]) -- underscores the priority to explore the mechanisms of advanced disease. The TP53 protein is an important clinical biomarker of breast cancer because of its association with tumour progression ([@bib35]), metastatic potential ([@bib10]), early relapse ([@bib1]), response to chemotherapy ([@bib1]; [@bib23]; [@bib6]), and ultimately, to prognosis and survival ([@bib8]; [@bib4]; [@bib37]). It is also of relevance to molecular subtypes of breast cancer ([@bib33]; [@bib26]). Whereas ∼70% of breast cancers with wild-type *TP53* are mostly of the Luminal A subtype, mutant *TP53* is common in the remaining 30%, which have a poorer prognosis and are classified as triple negative or luminal B. The focus of this work is to identify diagnostic, prognostic and therapeutic biomarkers associated with pathways perturbed by *TP53* mutations and understand their relationship to patient survival in breast cancer, under current therapeutic protocols.

TP53 is a key regulator of programmed cell death, cell cycle, DNA repair and genomic stability. In response to stimulus-specific post-transcriptional modification, TP53 regulates genes, which activate specific cellular programs. The TP53 protein has three major functional domains: a transactivation domain at its N-terminal, a central DNA-binding domain (which includes mutation hotspots) and tetramerization and regulatory domains at the C-terminal. The location and type of *TP53* mutation affect the ability of TP53 to regulate its target genes, leading to aberrant functions ([@bib7]) with clinical implications ([@bib25]). Characterisation of the differential activation of key pathways and candidate genes according to the TP53 mutation status may therefore identify mechanisms correlated with *TP53* mutation status in breast cancer.

In this study, we stratify breast cancers based on their *TP53* mutation status and identify the set of dysregulated tumorigenic pathways and their candidate driver genes by using gene expression data sets obtained from tumours. The goal is to infer the class-specific candidate gene signature by identifying weak to moderate, but coherent gene expressions that significantly influence tumorigenic pathways and survival.

Results
=======

We first categorised breast cancer samples by their corresponding *TP53* mutation status, as described in [Supplementary Table 1](#sup1){ref-type="supplementary-material"} and performed analysis as shown in the flow-chart ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

Candidate driver pathways differentially perturbed by *TP53* mutations
----------------------------------------------------------------------

Enrichment analysis of pathways between mutation status classes was performed using globaltest ([@bib18]) and *SAM-GS* ([@bib13]) on the primary and combined validation data set. Globaltest, although being sensitive to genes with smaller regression coefficients, its results might be influenced by the standardisation and normalisation procedures. SAM-GS on the other hand is shown to have relatively higher power in the lower alpha-level region, thus can better focus on pathways of greatest interest ([@bib29]). Therefore, we use a combination of the two approaches here. The list of differentially enriched KEGG ([@bib24]) pathways identified by each of the methods on each of the data set is shown together in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}. A set of 40 pathways inferred as commonly significant by both the methods in both data sets ([Table 1](#tbl1){ref-type="table"}) -- are graphically presented as an enrichment map color-coded according to globaltest FDR corrected *P*-values ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). The most dysregulated pathways included a group of key signalling pathways -- such as p53 signalling, calcium signalling, MAPK, ErbB, vascular endothelial growth factor (VEGF) signalling and various cancer pathways.

Candidate genes deregulated according to the *TP53* mutation status
-------------------------------------------------------------------

Candidate genes were identified by applying a combination of two mutually complementary approaches: pathway-based gene-search that infers class-specific association (globaltest) and pathway-independent search that identifies individual genes with class-specific upregulation (modified Kolmogorov-Smirnov approach) on both primary and validation data sets ([Supplementary Tables 3 and 4](#sup1){ref-type="supplementary-material"}). Combining genesets inferred by these two approaches would help to account for the genes with smaller as well as larger effects on the overall biological condition. A consensus genelist ([Supplementary Table 5](#sup1){ref-type="supplementary-material"}) of 112 genes consists of genes inferred as significant at least by either of the two statistical tests (but not necessarily by the same test) in both primary and validation data sets, as shown in the Venn diagram ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). Class-specific predicted functional networks based on these genesets are plotted in [Figures 1A and B](#fig1){ref-type="fig"} for wild-type and mutant *TP53* samples, respectively. These networks reflect the key genes and corresponding processes that have potential functional implication in association with the one of the *TP53* mutation status class. Wild-type *TP53* samples showed significance of genes involved in estrogen receptor (ER) signalling, whereas mutant *TP53* samples in proliferative processes. Besides, GO terms--response to insulin stimulus and mammary gland development in wild-type and protein kinase activity, mitotic cell cycle, microtubule cytoskeleton in mutant *TP53* class were over-represented ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}).

Association of EMT and stemness to *TP53* mutation status
---------------------------------------------------------

Aberrant TP53 function is shown to induce epithelial-mesenchymal transition (EMT) and thereby confers stemness properties to the cancer cells ([@bib12]). Therefore, we compared our inferred *TP53* status-specific candidate genesets with the published EMT and stemness marker sets. We found that mutant *TP53*-marker geneset was significantly associated with embryonic stem cell (ESC) and its TP53 targets (p53ESC) genesets (*P*-value\<0.05). Whereas wild-type *TP53* signature was found significantly associated with PRC2 targets (*P*-value: 0.003) ([Table 2](#tbl2){ref-type="table"}). Top 1000 upregulated genes (according the signal-to-noise ratio) in mutant *TP53* class were significantly associated with EMT, ESC and induced pluripotent stem cell marker genesets. Moreover, KEGG pathways involved in stemness and EMT properties such as TGFβ, wnt signalling were found differentially enriched ([Supplementary Table 6b](#sup1){ref-type="supplementary-material"}).

Vascular endothelial growth factor A upregulation with wild-type *TP53* associates with activation of pro-angiogenic and pro-metastatic biological processes
------------------------------------------------------------------------------------------------------------------------------------------------------------

Among the inferred candidate genes that were found upregulated and/or significantly associated to one of the *TP53* mutation status class, 47 genes showed univariate significance to overall patient survival. Vascular endothelial growth factor A (*VEGFA*) maintained significance in multivariate model ([Supplementary Table 7](#sup1){ref-type="supplementary-material"}), even after adjusting for *TP53* mutation status. *VEGFA* might be induced by estrogen receptor in breast cancer cells ([@bib9]; [@bib2]). Besides, wild-type TP53 could block VEGFA function induced by active estrogen receptor signalling ([@bib28]). However, implications of *VEGFA* in wild-type *TP53*/ER+ patients are less understood. We therefore analysed this subgroup separately by using the globaltest and moderated *t-test* ([@bib41]).

Using moderated *t-test* of differential expression on a cross-platform compiled data set, we found 516 gene features ([Supplementary Table 8a](#sup1){ref-type="supplementary-material"}) differentially expressed between *VEGFA* upregulation (*VEGFA*+) *vs VEGFA* normal/− samples (*VEGFA*−/N). *IGF1* and *PPARG* were found differentially downregulated in samples with *VEGFA* upregulation. A GO analysis identified pathways associated with blood vessel morphogenesis, cell migration and regulation of VEGF signalling pathway. The complete list of over-represented GO terms and predicted functional interactions are shown in [Supplementary Table 9](#sup1){ref-type="supplementary-material"} and [Supplementary Figure 5](#sup1){ref-type="supplementary-material"}, respectively. Notably, *VEGFA*+ *vs* *VEGFA*−/N comparison for mutant *TP53* subgroup does not show any remarkable difference apart from differential expression of *VEGFA* itself and pH regulator *CA9* ([Supplementary Table 8b](#sup1){ref-type="supplementary-material"}).

Tumours overexpressing *VEGFA* (both ER+ wild-type *TP53* and mutant *TP53* irrespective of ER status) show a differential enrichment of the mTOR-signalling pathway compared with normal/downregulated *VEGFA* samples. *VEGFA*+/ER+ wild-type *TP53* samples showed significant association of *EIF4EBP1, MAPK1* (*P*-value\<0.05) and weak association of *MTOR, ULK3* and *RPTOR.* Conversely, *PIK3CA* and *IGF1* were significantly associated with *VEGFA* N/− tumours ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"} and [Supplementary Table 10a](#sup1){ref-type="supplementary-material"}). Interestingly, different sets of genes, although involved in the same pathways were found associated with *VEGFA* status in the mutant *TP53* subgroup ([Supplementary Table 10b](#sup1){ref-type="supplementary-material"}).

*TP53* mutation, ER status and *VEGFA* upregulation influence survival
----------------------------------------------------------------------

Samples were substratified according to the ER status in each *TP53* mutation class. While comparing the ER+/mutant *TP53* to the ER+/wild-type *TP53* samples, we noted a death hazard ratio (HR) of 2.15 (95% CI: 1.25--3.70) and likelihood *P*-value \<0.01. On the other hand, ER− samples showed weaker significance (*P*=0.2; HR: 2.6; 95% CI: 1.14--5.91). As progesterone receptor (PgR) positivity is a better marker of active ER signalling ([@bib3]), we also used PgR status as an indicator of active ER signalling. PgR+ samples showed a significant survival difference between mutant and wild-type tumours (*P*=1.53e−05, HR: 7.2, 95% CI: 3.03--17.1). However, PgR-tumours do not show significant survival differences (*P*\>0.1) ([Figure 2A and B](#fig2){ref-type="fig"}). On the basis of these findings, we propose that active ER signalling can influence the effect of mutant TP53 on survival.

As *VEGFA* expression is observed here as a significant influencer on survival even after controlling for *TP53* status, we reanalyzed the above effects by adding *VEGFA* expression status as a covariate. Among ER+ group, the overall patient survival was significantly influenced by *TP53* mutation status and *VEGFA (*model significance=0.0005) with their corresponding HR=2.02 and 2.08, compared with baseline risk for wild-type *TP53* and *VEGFA* normal/downregulation. Even stronger effect was observed after excluding samples with non-missense mutant *TP53* (*P*-value=0.0001, HR=2.38 and 2.11, respectively). Survival effect of *TP53* mutation status and *VEGFA* was stronger in PgR+ cases (HR=2.35, 95% CI: 1.17--4.74 for *VEGFA* upregulation, HR=5.2, 95% CI: 2.43--11.1 for mutant *TP53* status, and overall likelihood ratio test *P*=2.76e−6), but non-significant effect in PgR--cases ([Figure 2C and D](#fig2){ref-type="fig"}). Although active ER signalling in general is known to predict better prognosis, these findings show that irrespective of the TP53 mutation status, ER+ cases with high mRNA levels of *VEGFA* indicates poor prognosis. Interestingly, despite of the lowest occurrence of cases with upregulated *VEGFA* in ER+/wtTP53 subgroup ([Supplementary Figure 6](#sup1){ref-type="supplementary-material"}), its prognostic significance underscores further exploration.

Discussion
==========

Our findings show predominance of ER signalling in breast cancers with wild-type *TP53,* marked by the upregulation of *ESR1*, GATA-binding protein 3, retinoic acid receptor alpha (*RARα*) and *CA12*. Estrogen receptor *α*, a direct transcriptional activator of RAR*α* ([@bib19]), mediates anti-proliferative response by vitamin A metabolite (all-*trans*-retinoic acid ) in breast cancer cells ([@bib11]). Retinoic acid receptor *α* is a rate-limiting factor for ER transcriptional activity ([@bib40]). Co-expression of *BCL2, ERBB4, IGF1R, IRS1* was also found in this group. Our observation of consistent upregulation of *CA12, AGR3, IL6ST* and *STC2* genes is in agreement with their previously reported association with ER+ breast cancers. Our findings also showed upregulation of *SIRT3*, a mitochondrial p53 activity regulator, necessary for averting TP53-mediated growth arrest ([@bib27]). Predicted functional network ([Figure 1A](#fig1){ref-type="fig"}) provides a hint that genes involved in ER signalling form a core group of interactions in *TP53* wild-type tumours. A strong relationship between ER signalling and TP53 can be observed in our results. This relationship also has got implications on proliferation and treatment responsiveness. The presence of wild-type TP53 improves sensitivity to Tamoxifen ([@bib4]) and inhibits ER cross-talk with the EGFR/HER2 pathways ([@bib16]). Experimental observations have provided evidence about potential direct ER--TP53 interactions ([@bib30]). However, these complex interactions and their effects on transactivation activity of TP53 and ERα in ER+ breast cancer remains to be understood. Given that *TP53* status is an important predictor of response in patients receiving therapy targeting the ER pathway (SERM), we expect that TP53 retains a subset of functions necessary for the response to such therapy.

Genes in pathways related to cell cycle, angiogenesis, chromosomal instability and metastasis were significantly affected in mutant *TP53* tumours. We found the gene *BUB1* and spindle-checkpoint associated kinases were significantly associated with *TP53* mutant tumours. In the presence of dysfunctional TP53, their aberrant expression can cause genomic instability, leading to aneuploidy and malignant transformation ([@bib17]). Other genes associated with mutant *TP53* included ones involved in proliferation, angiogenesis and metastasis-*VEGFA, HIF1α, E2F1, CDK6* and *EGFR.*

*VEGFA* upregulation is an important indicator of pro-angiogenic and pro-metastatic activity. Dysregulation of TP53-VEGF signalling may potentially be a key event in breast cancers with mutant *TP53.* Mutant *TP53* may facilitate this tumorigenic programme by: passing the direct survival advantage to malignant cells, by facilitating the VEGF-mediated enhanced cell migration, angiogenesis and metastasis or by overcoming the regulation by *ETS1* ([@bib14]). Active ER signalling and mutant TP53 are also reported to activate VEGF and mark poor prognosis ([@bib5]). In our data, we see that mutant *TP53* and VEGF upregulation significantly affects patient survival in ER+/PgR+ samples, but not in ER−/PgR− samples. Activation of VEGFA may also be attributed to the expression of EGFR ([@bib31]) or CDK6, which can correlate with the expression of mutant TP53 ([@bib44]) and potentially delay cell senescence. Thus, besides the direct effects of lost TP53 function, other related opportunistic mechanisms, such as dysregulated proliferative effects of VEGFA may contribute the overall manifestation.

ER+/wild-type *TP53* samples showed relatively low occurrence of *VEGFA* upregulation but poor survival profile. ER-mediated induction of VEGF ([@bib5]; [@bib2]) and VEGF regulation by TP53 ([@bib28]) suggests a complex interplay between these three signalling mechanisms. This group also showed the differential enrichment of mTOR signalling. Co-activation of VEGF and mTOR pathway components has been previously reported ([@bib43]). Thus, VEGFA may represent a biomarker of interest to identify the target subset of ER+ breast cancer patients who might benefit from early administration of VEGFA or mTOR-targeted therapy.

Materials and Methods
=====================

Agilent chip based gene expression data for a subset of 111 breast cancer cases from ([@bib15]) GEO (accession number GSE19783) was used as the primary data set. *TP53* mutations for the primary data in coding regions of exons 2--11 and clinical data were obtained from ([@bib34]). Expression data used for validation was obtained from GEO (accession number GSE3494) and from Stanford Microarray Database. Clinical and *TP53* data for these data sets were obtained from ([@bib33]; [@bib26]).

Methods used to merge data sets to form a validation data set
-------------------------------------------------------------

Two expression data sets ([@bib33]; [@bib26]) from independent studies and different technology platform were preprocessed, quantile normalised and combined based on UniGene identifiers. Batch effects were corrected by applying parametric empirical Bayes method ([@bib22]).

Differential enrichment of pathways and candidate genes
-------------------------------------------------------

The globaltest ([@bib18]) uses a regression model where genes are covariates and sample classes are response variables. Significant association of gene means significant non-zero regression coefficient of a gene in a geneset (here a particular KEGG pathway). SAM-GS is another geneset enrichment analysis method based on the *t*-like statistic for assessing the permutation-based significance of association between an individual pathway and a phenotype of interest. KEGG pathways inferred as significant by globaltest at FDR corrected *P*-value of 10*e*−5 and validated by SAM-GS ([@bib13]) at FDR corrected *P*-value cutoff=10*e*−6 on both primary and validation data sets were analysed by *post-hoc* covariate test to identify significant genes. Gene upregulation means its class-specific upward biased expression pattern, inferred by the rank-sum statistic of the modified Kolmogorov--Smirnov test ([@bib45]).

Class-specific predicted functional interactions between genes in the genesets were obtained from STRING database ([@bib21]).

Pathways enrichment and GO analysis
-----------------------------------

Gene Ontology (GO) analysis was performed for each *TP53* mutation status-specific genesets using DAVID ([@bib20]) by Fisher\'s exact test with human whole genome as a background. Differentially enriched pathways and GO terms were graphically presented as Enrichment map ([@bib32]), with nodes color-coded by FDR-adjusted *P*-value of significance and node-size proportionate to number of genes in the pathway. Fraction of overlapping genes between any two pathways is represented by the edge thickness, with cutoff overlap coefficient of 0.1.

Association of TP53 biology with EMT and stemness marker signatures
-------------------------------------------------------------------

Inferred class-specific genesets were tested by hypergeometric test for their association to the published EMT and stemness marker genesets shown in [Supplementary Table 6a](#sup1){ref-type="supplementary-material"}. A larger genelist inferred by using signal-to-noise ratio between *TP53* mutation status classes was also tested for its association to these published genesets.

Survival analysis
-----------------

A combined cohort of 438 cases obtained by merging clinical data from three individual clinical data sets ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}) was used. Kaplan--Meier estimation of survival and computation of Cox proportional hazards frailty model for the death event was performed by using R package *survival* ([@bib42]). Inferred candidate genes were assessed for their uni-/multivariate effect on survival. The effect of TP53 mutation status together with genes that maintain significance in a multivariate model (*VEGFA* expression status) and predicted subtype ([@bib38])- was computed with and without stratification by ER/PgR status.

Discretisation of gene expression
---------------------------------

The mRNA expression levels of candidate genes were discretised into two levels using mean (*μ*)+0.5\*standard deviation (s.d.) as a cutoff in each data set.

Analysis was performed by using R ([@bib39]).
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![*TP53* mutation status-specific network of potential candidate driver genes shown based on their known and predicted functional interactions. (**A**) Network for wild-type *TP53* breast cancer profiles. (**B**) Network for mutant *TP53* breast cancer profiles. Significant association of gene means significant non-zero regression coefficient of a gene in a significantly differentially enriched KEGG pathway. Gene upregulation means its class-specific upward biased expression pattern, inferred by the rank-sum statistic of the modified Kolmogorov--Smirnov test. Relevant biological processes represented by these genes are also highlighted in background.](bjc2012461f1){#fig1}

![Overall patient survival differs significantly according to the *TP53* mutation status and *VEGFA* expression status in PgR+ and PgR− subgroups of patients. Survival differences between wild-type *TP53* and mutant *TP53* in each of the subgroups are shown in Kaplan--Meier plots shown in **A** and **B**. Survival differences of four classes: (1) wild-type *TP53* and *VEGFA* normal/downregulation (wt*TP53* *VEGFA* N/−); (2) wild-type *TP53* and *VEGFA* upregulation (wt*TP53* *VEGFA*+); (3) mutant *TP53* and *VEGFA* normal/downregulation (mt*TP53* *VEGFA* N/−); and (4) mutant *TP53* and *VEGFA* upregulation (mt*TP53* *VEGFA*+) -- in PgR+ and PgR− subgroups are shown in **C** and **D**. Significance of overall model is based on the likelihood ratio test *P*-value.](bjc2012461f2){#fig2}

###### Consensus list of differentially enriched pathways between two *TP53* mutation status classes (wild-type *TP53* profiles compared with the mutant *TP53* profiles), based on pathway analysis performed by using two approaches -- globaltest and SAM-GS on primary (*n*=111 samples) and validation data sets (a combined cross-platform data set with *n*=327)

                                                                                       **Primary data set**             **Validation data set**                                          
  ------------ --------------------------------------------------------------- ------------------------------------ ------------------------------- ------------------------------------ -------------------------------
                                                                                    **Asymptotic global test**                **SAM-GS**                 **Asymptotic global test**                **SAM-GS**
  **KEGGID**   **KEGG pathway name**                                            **BH corrected** ***P*****-value**   **FDR adj** ***P*****-value**   **BH corrected** ***P*****-value**   **FDR adj** ***P*****-value**
  hsa:00230    Purine metabolism                                                             1.8E−09                            \<10e−6                           2.37E−36                           \<10e−6
  hsa:04115    p53-signalling pathway                                                        1.8E−09                            \<10e−6                           2.43E−34                           \<10e−6
  hsa:05211    Renal cell carcinoma                                                          3.72E−09                           \<10e−6                           1.32E−17                           \<10e−6
  hsa:05200    Pathways in cancer                                                            1.1E−08                            \<10e−6                           6.86E−29                           \<10e−6
  hsa:05215    Prostate cancer                                                               1.1E−08                            \<10e−6                           1.32E−29                           \<10e−6
  hsa:04020    Calcium-signalling pathway                                                    4.12E−08                           \<10e−6                           4.81E−27                           \<10e−6
  hsa:00260    Glycine, serine and threonine metabolism                                      4.73E−08                           \<10e−6                           1.44E−25                           \<10e−6
  hsa:05212    Pancreatic cancer                                                             5.65E−08                           \<10e−6                           1.15E−39                           \<10e−6
  hsa:04340    Hedgehog-signalling pathway                                                   6.02E−08                           \<10e−6                           5.76E−21                           \<10e−6
  hsa:05222    Small-cell lung cancer                                                        7.93E−08                           \<10e−6                           6.75E−40                           \<10e−6
  hsa:04120    Ubiquitin-mediated proteolysis                                               0.00000012                          \<10e−6                           3.26E−40                           \<10e−6
  hsa:04910    Insulin signalling pathway                                                   0.00000012                          \<10e−6                           5.83E−27                           \<10e−6
  hsa:00051    Fructose and mannose metabolism                                               1.28E−07                           \<10e−6                           2.51E−30                           \<10e−6
  hsa:05218    Melanoma                                                                     0.00000014                          \<10e−6                           1.7E−17                            \<10e−6
  hsa:04150    mTOR-signalling pathway                                                       1.68E−07                           \<10e−6                           9.66E−26                           \<10e−6
  hsa:00380    Tryptophan metabolism                                                         1.96E−07                           \<10e−6                           1.48E−08                           \<10e−6
  hsa:04144    Endocytosis                                                                   2.39E−07                           \<10e−6                           4.96E−24                           \<10e−6
  hsa:00330    Arginine and proline metabolism                                              0.00000025                          \<10e−6                           1.29E−18                           \<10e−6
  hsa:05214    Glioma                                                                       0.00000025                          \<10e−6                           1.47E−14                           \<10e−6
  hsa:04010    MAPK-signalling pathway                                                      0.00000031                          \<10e−6                           2.44E−34                           \<10e−6
  hsa:04012    ErbB-signalling pathway                                                       3.65E−07                           \<10e−6                           2.68E−17                           \<10e−6
  hsa:04520    Adherens junction                                                             4.03E−07                           \<10e−6                           9.78E−13                           \<10e−6
  hsa:05217    Basal cell carcinoma                                                         0.00000048                          \<10e−6                           6.47E−11                           \<10e−6
  hsa:00600    Sphingolipid metabolism                                                       4.94E−07                           \<10e−6                           4.67E−14                           \<10e−6
  hsa:05120    Epithelial cell signalling in *Helicobacter pylori* infection                 5.79E−07                           \<10e−6                           1.45E−11                           \<10e−6
  hsa:04722    Neurotrophin-signalling pathway                                               6.72E−07                           \<10e−6                           1.09E−21                           \<10e−6
  hsa:04912    GnRH-signalling pathway                                                       8.22E−07                           \<10e−6                            6E−18                             \<10e−6
  hsa:05219    Bladder cancer                                                                8.23E−07                           \<10e−6                           1.61E−17                           \<10e−6
  hsa:05210    Colorectal cancer                                                            0.00000116                          \<10e−6                           3.9E−11                            \<10e−6
  hsa:04070    Phosphatidylinositol-signalling system                                       0.00000117                          \<10e−6                           2.16E−12                           \<10e−6
  hsa:04110    Cell cycle                                                                   0.00000125                          \<10e−6                           3.7E−27                            \<10e−6
  hsa:04370    VEGF-signalling pathway                                                      0.00000153                          \<10e−6                           1.01E−07                           \<10e−6
  hsa:05221    Acute myeloid leukaemia                                                      0.00000205                          \<10e−6                           6.36E−12                           \<10e−6
  hsa:00270    Cysteine and methionine metabolism                                           0.0000036                           \<10e−6                           1.24E−25                           \<10e−6
  hsa:04530    Tight junction                                                               0.00000531                          \<10e−6                           6.85E−18                           \<10e−6
  hsa:04350    TGF-*β*-signalling pathway                                                   0.00000725                          \<10e−6                           5.93E−14                           \<10e−6
  hsa:04310    Wnt-signalling pathway                                                       0.0000103                           \<10e−6                           8.24E−19                           \<10e−6
  hsa:00590    Arachidonic acid metabolism                                                  0.0000146                           \<10e−6                           1.16E−11                           \<10e−6
  hsa:05213    Endometrial cancer                                                            0.000018                           \<10e−6                          0.00000131                          \<10e−6
  hsa:04142    Lysosome                                                                     0.0000489                           \<10e−6                           6.09E−18                           \<10e−6

Abbreviations: BH, Benjamini-Hochberg; FDR, false discovery rate; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; SAM-GS, significance analysis of microarrays for genesets; TGF, tumour growth factor; VEGF, vascular endothelial growth factor.

The full pathway lists that show significance of differential enrichment in each individual data set are shown with their respective *P*-values of significance in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}.

###### Association between the inferred *TP53* mutation status-specific signatures with previously reported EMT and stemness markers. Statistical significance of differential expressed geneset overlapping the stemness and epithelial-mesenchymal transition (EMT) marker genelists[a](#t2-fn2){ref-type="fn"}. Statistical significance was computed by applying hypergeometric test[b](#t2-fn3){ref-type="fn"}

                                                          **wt*****TP53*** **signature**    **Mutant** ***TP53*** **signature**   **Top 1000 genes ranked acc to absolute SNR (wt** ***vs*** **mt*****TP53*** **BC)**   **Top 1000 mt*****TP53*****-upregulated genes ranked acc to SNR**                                                                                          
  ------------------------------------------------------ --------------------------------- ------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------- --------------------------------- ------------------- --------------------------------- -------------------
  **EMT and stemness geneset and its transcript size**    **Number of overlapping genes**            ***P*****-value**                                      **Number of overlapping genes**                                                     ***P*****-value**                           **Number of overlapping genes**   ***P*****-value**   **Number of overlapping genes**   ***P*****-value**
  EMT (*n*=497)                                                          0                                  NS                                                             1                                                                           NS                                                 11                         NS                         15                        0.031
  ESC (*n*=553)                                                          0                                  NS                                                            14                                                                        2.65E−13                                              22                      2.60E−04                      35                      4.34E−11
  PRC2 (*n*=1016)                                                        7                               3.25E−03                                                          0                                                                           NS                                                 25                         NS                         19                         NS
  iPSC (*n*=597)                                                         1                                  NS                                                             3                                                                           NS                                                 17                      4.50E−02                      22                      1.50E−03
  p53esc (*n*=912)                                                       2                                  NS                                                             5                                                                        2.66E−02                                              12                         NS                         15                         NS

Abbreviations: BC, breast cancer; ESC, embryonic stem cell; iPSC, induced pluripotent stem cell; NS, not significant; p53esc, p53 targets identified in murine embryonic stem cells; PRC2, polycomb repressive complex 2; SNR, signal-to-noise ratio.

Sources of the genelists are described in the [Supplementary Table 6A](#sup1){ref-type="supplementary-material"}.

Statistical significance was evaluated by Fisher\'s exact test, in instances where number of overlapping genes ⩽5.
